EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas

Giulia Cossu iD, Stefano La Rosa, Jean Philippe Brouland, Nelly Pitteloud, Ethan Harel, Federico Santoni iD, Maxime Brunner, Roy Thomas Daniel, Mahmoud Messerer

Cancers · 08.09.2023 · 15 (18) · 4471

DOI: 10.3390/cancers15184471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 08.09.2023. Verfasst von Giulia Cossu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service of Neurosurgery, University Hospital of Lausanne, University of Lausanne, 1005 Lausanne, Switzerland. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brihaye EANS Research, Swiss National Science Foudation, Novartis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim: About a third of Pituitary Neuroendocrine Tumors (PitNETs) may show aggressive behavior. Many efforts have been performed for identifying possible predictive factors to early determine the future behavior of PitNETs. Programmed cell death ligand 1 (PD-L1) expression was associated with a more aggressive biology in different solid tumors, but its role in PitNET is not well-established yet. Our study aims to analyze PD-L1 expression in a surgical cohort of PitNETs to determine its association with radiological invasion and pathology findings, as well as with long-term recurrence rates.

Methods

We performed a retrospective analysis in a series of 86 PitNETs. Clinical presentation and radiological features of the preoperative period were collected, as well as pathological data and follow-up data. The rate of PD-L1 expression was immunohistochemically evaluated and expressed as a tumor proportion score (TPS). We assessed its relationship with cavernous sinus invasion and Trouillas’ classification as primary outcomes. Secondary outcomes included the TPS’ relationship with histopathological markers of proliferation, hormonal expression, tumor size and long-term recurrence rates. We calculated the optimal cut-point for the primary outcomes while maximizing the product of the sensitivity and specificity and then we evaluated the significance of secondary outcomes with logistic regression analysis.

Results

Eighty-six patients were included in the analysis; 50 cases were non-functional PitNETs. The TPS for PD-L1 showed a highly right-skewed distribution in our sample, as 30.2% of patients scored 0. Using Trouillas’ classification, we found that “proliferative” cases have a significantly higher probability to express PD-L1 in more than 30% of tumor cells (OR: 5.78; CI 95%: 1.80–18.4). This same cut-point was also associated with p53 expression. A positive association was found between PD-L1 expression and GH expression (p = 0.001; OR: 5.44; CI 95%: 1.98–14.98), while an inverse relationship was found with FSH/LH expression (p = 0.014; OR = 0.27, CI 95%: 0.10–0.76). No association was found with CS invasion, tumor size, bone erosion or dura invasion. We could not find any association between PD-L1 expression and recurrence.

Conclusions

PD-L1 expression was associated with proliferative grades of Trouillas’ classification and p53 expression. We also confirmed a higher expression of PD-L1 in somatotroph tumors. Larger studies are necessary to investigate the relationship between PD-L1 expression and aggressive behaviors.

Schlagwörter

Stichwörter der Autor:innen

PD-L1PitNETbiological behaviorgonadotroph pituitary tumorsimmune checkpoint inhibitorsimmunotherapypituitary adenomaprognosissomatotroph pituitary tumors

Autor:innen und Institutionen

  • Service of Neurosurgery, University Hospital of Lausanne, University of Lausanne, 1005 Lausanne, Switzerland.
  • Unit of Pathology, Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.
  • Department of Laboratory Medicine and Pathology, Institute of Pathology, University of Lausanne, 1005 Lausanne, Switzerland.
  • Department of Endocrinology, University Hospital of Lausanne, University of Lausanne, 1005 Lausanne, Switzerland.

ORCID-Profile: Giulia Cossu, Federico Santoni

Förderung

  • Brihaye EANS Research
  • Swiss National Science Foudation
  • Novartis Foundation

Zitieren

APA

Cossu, G., La Rosa, S., Brouland, J. P., Pitteloud, N., Harel, E., Santoni, F., Brunner, M., Daniel, R. T., & Messerer, M. (2023). PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas. Cancers, 15(18), 4471. https://doi.org/10.3390/cancers15184471

Vancouver

Cossu G, La Rosa S, Brouland JP, Pitteloud N, Harel E, Santoni F, et al. PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas. Cancers. 2023;15(18):4471. doi:10.3390/cancers15184471

BibTeX
@article{Cossu2023,
  author = {Cossu, Giulia and La Rosa, Stefano and Brouland, Jean Philippe and Pitteloud, Nelly and Harel, Ethan and Santoni, Federico and Brunner, Maxime and Daniel, Roy Thomas and Messerer, Mahmoud},
  title = {PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {18},
  pages = {4471},
  doi = {10.3390/cancers15184471}
}
Kostenlos starten →